Medical device company Bigfoot Biomedical Inc disclosed on Monday that secured USD45m from the initial tranche of a Series C equity financing.
The round is led by Abbott with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, as well as Cormorant Asset Management.
Proceeds will be used to support the completion of product development and FDA clearance for the Bigfoot Unity Diabetes Management Programme, an injection-based digitized insulin dosing platform utilizing a proprietary, connected insulin pen-based system that integrates Abbott's FreeStyle Libre glucose sensing technology. Submission is anticipated in 2020 with a target launch by year-end 2020.
In addition, the Series C funds will be directed toward clinical trials of future generation Bigfoot Unity systems incorporating closed-loop technology for injection users.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
Alvotech and Advanz Pharma sign European deal for Cimzia biosimilar
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies